Yes that data is interesting, it shows how often the CDH17...

Yes that data is interesting, it shows how often the CDH17 protein is present in different types of gastrointestinal cancers.

Specifically:Colorectal cancer: Out of 821 samples, 96% of the cases had CDH17 present on the cancer cells.

Neuroendocrine tumors of the midgut and hindgut: Out of 119 samples, 97% had CDH17 expression.

Gastric cancer: Out of 1,409 samples, only 64% of the cases showed CDH17 expression.

This information is crucial because the therapy being tested (CHM-2101 CAR T-cells) is designed to target cancer cells that express CDH17. It means that colorectal cancer and neuroendocrine tumors are more likely to respond to this treatment, as nearly all of these cancer cases have the target protein.

For gastric cancer, the treatment might only work for the subset of patients whose tumors express CDH17, which is why screening is required for these patients before they can receive the therapy.

Once this moves, it will move fast. We just need some data to ignite some serious interest.

Wont be long.

All IMO.